These presentations will include: (1) monotherapy in BRAF V600 mutant solid tumors ... Continued to progress its internal discovery portfolio of orally bioavailable degraders. Corporate: C4T further ...
PetVivo has developed a robust pipeline of products for the medical treatment of animals and people, with a portfolio of 21 patents that protect the company's biomaterials ... SEC filings, public ...